EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma

Zhao Wang, Haotian Liu, Xueqi Wang, Jianjin Teng, Zihan Zheng, Jingya Zhang, Wanyi Xiao, Qian Liang, Jiaxin Li, Xiaomeng Jia, Xin Feng, Hongzhang Cui und 8 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202515158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Zhao Wang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center f…. Hauptthemen laut MEDLINE: MicroRNAs, Melanoma, Drug Resistance, Neoplasm, CD8-Positive T-Lymphocytes. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, National Key Laboratory Major Special Project of Tianjin Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired resistance to both targeted therapies and immunotherapies in cancer presents major clinical challenges, yet the molecular mechanisms underlying cross‐resistance remain poorly understood. We hypothesized that loss of specific microRNAs (miRNAs) could potentiate melanoma resistance to both targeted drugs and CD8 + T cell‐mediated cytotoxicity. Through genome‐wide miRNA CRISPR knockout screening integrated with cellular models, longitudinal clinical samples, and in vivo experiments, we identified miR‐18a as a pivotal upstream regulator of pleiotropic resistance in melanoma. We show that miR‐18a deficiency drives resistance through two distinct mechanisms: derepressing AJUBA‐regulated Hippo signaling during MAPK inhibition, and enhancing THBS1–CD47 interactions that impair the immunological synapse between tumor cells and CD8 + T cells. Furthermore, hnRNP A1 plays an essential role in modulating miR‐18a expression, thereby mediating cross‐resistance. These findings suggest that targeting non‐coding RNA vulnerabilities may represent a promising therapeutic strategy to overcome complex resistance mechanisms and improve clinical outcomes in melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsMelanomaDrug Resistance, NeoplasmCD8-Positive T-LymphocytesHumansAnimalsMiceCell Line, TumorCRISPR-Cas SystemsClustered Regularly Interspaced Short Palindromic Repeats

Stichwörter der Autor:innen

CRISPR screenT cell immunityTHBS1–CD47 axishippo signalingmelanomamiR‐18atargeted therapy resistance

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Department of Pharmacology, State Key Laboratory of Experimental Hematology, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Inflammation Biology…
  • Oujiang Laboratory, Wenzhou Medical University, Wenzhou, China.
  • Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, State Key Laboratory of Druggability Evaluation and Systematic Transla…
  • Department of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
  • Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
  • Scientific Research Center, Wenzhou Medical University, Wenzhou, China.

ORCID-Profile: Mulin Jun Li

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • National Key Laboratory Major Special Project of Tianjin Science and Technology Plan Project
  • Natural Science Foundation of Tianjin
  • Natural Science Foundation of Zhejiang
  • National Human Genetic Resources Sharing Service Platform
  • Oujiang Laboratory Research Launch Project
  • Cancer Biobank of Tianjin Medical University Cancer Institute and Hospital

Zitieren

APA

Wang, Z., Liu, H., Wang, X., Teng, J., Zheng, Z., Zhang, J., Xiao, W., Liang, Q., Li, J., Jia, X., Feng, X., Cui, H., Luo, M., Yang, T., Wu, L., Zhao, K., Yang, W., Li, M. J., Huang, D., & Yang, J. (2026). Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. Advanced Science. https://doi.org/10.1002/advs.202515158

Vancouver

Wang Z, Liu H, Wang X, Teng J, Zheng Z, Zhang J, et al. Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. Advanced Science. 2026. doi:10.1002/advs.202515158

BibTeX
@article{Wang2026,
  author = {Wang, Zhao and Liu, Haotian and Wang, Xueqi and Teng, Jianjin and Zheng, Zihan and Zhang, Jingya and Xiao, Wanyi and Liang, Qian and Li, Jiaxin and Jia, Xiaomeng and Feng, Xin and Cui, Hongzhang and Luo, Menghan and Yang, Tielong and Wu, Liuxing and Zhao, Ke and Yang, Weilong and Li, Mulin Jun and Huang, Dandan and Yang, Jilong},
  title = {Genome‐Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202515158}
}
Kostenlos starten →